Annual Drug Patent Expirations for BREO+ELLIPTA
Breo Ellipta is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from two suppliers. There are fourteen patents protecting this drug.
BREO ELLIPTA drug price trends.
Drug patent litigation for BREO ELLIPTA.
This drug has three hundred and fifty-seven patent family members in forty-two countries.
The generic ingredient in BREO ELLIPTA is fluticasone furoate; vilanterol trifenatate. Two suppliers are listed for this compound. Additional details are available on the fluticasone furoate; vilanterol trifenatate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
